{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:47:02Z","timestamp":1753876022216,"version":"3.41.2"},"reference-count":0,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish Cancer and Allergy Foundation"},{"DOI":"10.13039\/501100007231","name":"Stockholm Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007231","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bengt Ihre research fellowship"},{"name":"Bengt Ihre foundation"},{"name":"Region Stockholm"},{"DOI":"10.13039\/100010805","name":"Medical Research Council of Southeast Sweden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010805","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,4]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Patients with inflammatory bowel disease have an increased risk of colorectal cancer. There is a scarcity of large studies with a focus on rectal cancer in patients with inflammatory bowel disease. This study aimed to compare survival in resected patients with rectal cancer with and without inflammatory bowel disease.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This national population-based study used the Colorectal Cancer Data Base. All Swedish patients \u226518 years of age with a diagnosis of stage I\u2013III rectal cancer between 1997 and 2021, surgically treated with curative intent, were included and followed up until 2022. The outcome of interest was recurrence-free survival. Flexible parametric survival models adjusted for time since surgery, year of diagnosis, sex, age at diagnosis, and Charlson Co-morbidity Index were used to estimate proportional and time-dependent hazard ratios of recurrence-free survival with 95% confidence intervals.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Overall, 22 082 patients with rectal cancer were included, among whom 323 (1.5%) had inflammatory bowel disease. Neoadjuvant radiotherapy\/chemoradiotherapy was given to 55% and 63% of patients with and without inflammatory bowel disease respectively. The median follow-up time was 5.2 years (interquartile range (i.q.r.) 2.3\u201310) in patients with inflammatory bowel disease and 5.9 years (i.q.r. 2.9\u201310) in patients without inflammatory bowel disease. Based on the adjusted proportional hazards model, no overall difference in recurrence-free survival was found (HR 1.05, 95% c.i. 0.87 to 1.26). In the time-dependent adjusted model, patients with rectal cancer with inflammatory bowel disease experienced a lower recurrence-free survival during the first year after surgery (1 year HR 1.36, 95% c.i. 1.06 to 1.73), after which there was no difference in comparison with patients without inflammatory bowel disease (5 years HR 0.77, 95% c.i. 0.56 to 1.06).<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Despite lower recurrence-free survival during the first year among those with inflammatory bowel disease, there were no long-term differences between patients with or without inflammatory bowel disease.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/bjsopen\/zraf014","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T17:22:48Z","timestamp":1744910568000},"source":"Crossref","is-referenced-by-count":0,"title":["Treatment and survival of non-metastatic rectal cancer in patients with inflammatory bowel disease: nationwide cohort study"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5312-1023","authenticated-orcid":false,"given":"Erik","family":"Lundqvist","sequence":"first","affiliation":[{"name":"Department of Surgery, Vrinnevi Hospital , Norrk\u00f6ping ,","place":["Sweden"]},{"name":"Department of Biomedical and Clinical Sciences, Faculty of Health, Link\u00f6ping University , Link\u00f6ping ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Westberg","sequence":"additional","affiliation":[{"name":"Division of Surgery, Danderyd Hospital , Stockholm ,","place":["Sweden"]},{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline E","family":"Dietrich","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c5sa H","family":"Everhov","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset , Stockholm ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-9213","authenticated-orcid":false,"given":"P\u00e4r","family":"Myrelid","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Clinical Sciences, Faculty of Health, Link\u00f6ping University , Link\u00f6ping ,","place":["Sweden"]},{"name":"Department of Surgery, Link\u00f6ping University Hospital , Link\u00f6ping ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bengt","family":"Glimelius","sequence":"additional","affiliation":[{"name":"Department of Oncology and Pathology, Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"Department of Immunology, Genetics and Pathology, Uppsala University , Uppsala ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Martling","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"Department of Pelvic Cancer, Karolinska University Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Nordenvall","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"Department of Pelvic Cancer, Karolinska University Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,3,25]]},"container-title":["BJS Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjsopen\/article-pdf\/9\/2\/zraf014\/62702435\/zraf014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjsopen\/article-pdf\/9\/2\/zraf014\/62702435\/zraf014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T17:22:49Z","timestamp":1744910569000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjsopen\/article\/doi\/10.1093\/bjsopen\/zraf014\/8093188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/bjsopen\/zraf014","relation":{},"ISSN":["2474-9842"],"issn-type":[{"type":"electronic","value":"2474-9842"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,3,4]]},"article-number":"zraf014"}}